Following these sales, Roper retains direct ownership of 372,152 shares. Additionally, shares are held indirectly through family trusts, with 334,127 shares by the Christopher G. Roper Exempt Family Trust, 329,127 shares by the Peter S. Roper Exempt Family Trust, and 329,225 shares by the Thomas L. Roper Exempt Family Trust. An additional 82,000 shares are held by Roper's spouse.These sales were executed under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell company stock in compliance with insider trading laws. The company currently trades at 34.6 times earnings, with analysts projecting continued profitability for the year ahead. For comprehensive analysis and additional insights, investors can access the detailed Pro Research Report available on InvestingPro, covering this and 1,400+ other US stocks. The company currently trades at 34.6 times earnings, with analysts projecting continued profitability for the year ahead. For comprehensive analysis and additional insights, investors can access the detailed Pro Research Report available on InvestingPro, covering this and 1,400+ other US stocks.
Following these sales, Roper retains direct ownership of 372,152 shares. Additionally, shares are held indirectly through family trusts, with 334,127 shares by the Christopher G. Roper Exempt Family Trust, 329,127 shares by the Peter S. Roper Exempt Family Trust, and 329,225 shares by the Thomas L. Roper Exempt Family Trust. An additional 82,000 shares are held by Roper's spouse.
These sales were executed under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell company stock in compliance with insider trading laws.
In other recent news, The Vita Coco Co. reported mixed results in its Q3 2024 earnings call. Despite a 4% decrease in net sales to $133 million, primarily due to a 37% drop in private label sales, the company raised its full-year guidance for net sales and adjusted EBITDA. Vita Coco's net income for the quarter rose to $19 million, or $0.32 per diluted share, compared to $15 million, or $0.26 per diluted share, in the same period last year.
BofA Securities has maintained a Neutral rating on Vita Coco's stock, but raised its price target to $38.00 from the previous $30.00. This adjustment follows an assessment of the company's sales performance and recently resolved inventory issues. According to BofA Securities, the company is expected to see a 13.5% increase in sales for 2025, slightly above the consensus estimate of 12.5%.
In other company news, Vita Coco has addressed its inventory constraints, primarily due to temporary challenges in ocean freight availability and transit times, as mentioned in the company's third-quarter earnings call. The company also plans to increase production capacity for 2025 and 2026, aiming to operate at 80%-85% capacity. These are among the recent developments for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.